Carrie E. and Boisjolie، نويسنده , , Charlene R. and Sharkey، نويسنده , , Scott W. and Cannon، نويسنده , , Christopher P. and Brunette، نويسنده , , Doug and Haugland، نويسنده , , J.Mark and Thatcher، نويسنده , , Jackson L. and Henry، نويسنده , , Timothy D.، نويسنده ,
Because time to treatment in AMI is a critical factor in long-term outcome, it is important that complex trials designed to improve reperfusion therapy do not delay the time to treatment. Participation in the TIMI 5 trial did not significantly prolong our door-to-needle time. These results indicate that, if done carefully, complex, labor-intensive studies can be performed within a reasonable time limit. Care should be taken to design protocols incorporating easy drug preparation, informed consent by the ED, and efficiency of trial initiation.